BioAtla (NASDAQ:BCAB – Get Free Report) is expected to announce its Q3 2026 resultson Thursday, November 12th. Analysts expect BioAtla to announce earnings of ($7.00) per share and revenue of $5.59 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.
BioAtla (NASDAQ:BCAB – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.50) by $8.64. The business had revenue of $6.50 million for the quarter, compared to analysts’ expectations of $6.50 million.
BioAtla Trading Up 4.5%
Shares of NASDAQ:BCAB opened at $2.09 on Tuesday. The firm has a market cap of $3.48 million, a PE ratio of -0.08 and a beta of 0.53. BioAtla has a 12-month low of $1.07 and a 12-month high of $71.50. The company has a fifty day simple moving average of $1.58 and a 200 day simple moving average of $4.77.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioAtla in a research note on Monday, August 31st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $200.00.
View Our Latest Analysis on BioAtla
BioAtla Company Profile
BioAtla, Inc was a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company used its Conditionally Active Biologics (CAB) platform to design antibody-based medicines intended to become active primarily within the tumor microenvironment, with the goal of improving treatment effectiveness while limiting effects on healthy tissue.
BioAtla’s investigational pipeline included antibody-drug conjugates and immune-modulating therapies. Its lead programs included mecbotamab vedotin, an antibody-drug conjugate designed to target AXL, and ozuriftamab vedotin, an investigational therapy directed at ROR2.
Featured Stories
- Five stocks we like better than BioAtla
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.
